Drug Profile
Meningococcal vaccine group C conjugate - GlaxoSmithKline
Alternative Names: MenC-CRM conjugate vaccine; Meningococcal C-CRM197 conjugate vaccine; MenjugateLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Novartis
- Class Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Meningococcal group C infections
Most Recent Events
- 04 Jan 2018 inVentiv Health has merged with INC Research to form Syneos Health
- 31 Aug 2017 GlaxoSmithKline completes a phase I trial for Meningococcal group C infections (In volunteers) in Germany (IM) (NCT02639351)
- 01 Mar 2016 GlaxoSmithKline initiates a phase I trial for Meningococcal group C infections (In volunteers) in Germany (IM) (NCT02639351)